Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-acetyl-11-keto-beta-boswellic acid
- Development stage
- Unknown
- Lead developer
- Sultan Qaboos University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
3-acetyl-11-keto-beta-boswellic acid (AKBA) is a pentacyclic triterpene small molecule derived from the resin of *Boswellia serrata* (Indian frankincense). It acts as a selective, non-competitive inhibitor of the 5-lipoxygenase (5-LOX) enzyme, which is responsible for the production of pro-inflammatory leukotrienes. Developed primarily by Sultan Qaboos University, AKBA is being investigated for the treatment of nephrolithiasis (renal stones), where it is formulated as 'Luban' capsules. Beyond its anti-inflammatory and litholytic potential, AKBA has shown preclinical activity in various cancers and renoprotective effects via the Klotho/TGF-beta/Smad signaling pathway.
- Brand names
- Luban
- Other names
- 3-acetyl-11-keto-beta-boswellic acidacetyl-11-keto-beta-boswellic acidacetyl11-keto-beta-boswellic acidacetyl 11-keto-beta-boswellic acid3-O-acetyl-11-keto-beta-boswellic acid3-acetyl-11-keto-ß-boswellic acid
02
Targets
CTSG (Cathepsin G)TOP2A (DNA topoisomerase II)ALOX5 (Arachidonate 5-lipoxygenase)ALOX12 (Arachidonate 12-lipoxygenase, 12S type)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on 3-acetyl-11-keto-beta-boswellic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3-acetyl-11-keto-beta-boswellic acid.